martes, 14 de septiembre de 2010
Entrevista al Dr. Saldaña en Ayer y Hoy: Enucleacion con Laser verde HPS
domingo, 8 de agosto de 2010
lunes, 5 de julio de 2010
VASO VASOSTOMÍA
- Tiempo desde la vasectomía.
- Nivel de la obstrucción
- Técnica quirúrgica a utilizar.
- Experiencia del cirujano.
Médico - Urólogo
-----------------------------------------------
Centro De Urología Avanzada de Lima (CUAL).
Clínica Padre Luis Tezza.
Av. Aviación 3161. Of 201. San Borja. Lima. PERU
Tel: (511) 475.65.24
Tele fax: (511) 226.82.74
jsaldanag@gmail.com
www.urologia.com.pe / www.urologia.pe
lunes, 21 de junio de 2010
Litotricia intracorporea
La litiásis renal o "cálculos renales", es una enfermedad que afecta aproximadamente al 10% de la población en edad adulta y con mayor frecuencia al sexo masculino.
Los "cálculos" pueden ubicarse en cualquier parte del tracto urinario y ocacionar dolor (cólicos) que puede llegar a ser muy intenso asi como también presencia de sangre en la orina.
Los cálculos se forman por un aumento de cierta sustancia que contiene la orina normalmente; pero al haber el aumento de esta sustancia se cristaliza y solidifica.
El tratamiento en algunos casos puede ser medico y con un aumento en la ingesta de agua; pero hay unos casos en los que es necesaria una intervención quirúrgica.
Antiguamente era necesaria una operación abierta para poder retirar el cálculo de las vías urinarias, hoy en dia existen tratamientos menos invasivos como la llamada LITOTRICIA INTRACORPOREA.
Definición
Esta técnica utiliza un aparato llamado ureterorrenoscopio que se introduce por la uretra y se exploran las vias urinarias hasta encontrar al cálculo, luego se introduce un filamento que genera descargas ultrasonicas que van fragmentando el cálculo hasta poder ser extraidos o eliminados.
Este procedimiento no requiere de corte y es completamente ambulatorio (solamente se necesitan 3 o 4 horas de descanso post-operatorio).
Es necesario recalcar que todo cálculo que después de 45 dias de tratameinto médico si no es expulsado tiene indicación quirúrgica, debido a que la función del riñón se compromete enormemente.
lunes, 24 de mayo de 2010
Certificados
miércoles, 28 de abril de 2010
Vaporizacion o Enucleacion con Green Light HPS
domingo, 18 de abril de 2010
reportaje en diario La republica sobre ENUCLEACION PROSTATICA
domingo, 4 de abril de 2010
Vasectomia sin bisturi
sábado, 20 de marzo de 2010
Mas informacion del TURIS
INTRODUCTION: The objective of this prospective randomized controlled study was to compare transurethral resection of the prostate in saline (TURPis) using the TURis system with the standard monopolar TURP, to determine evidence of safety and efficacy.
METHODS: Patients with symptomatic benign prostatic hyperplasia (BPH), aged 50 years or older, with estimated prostate volume (PV) ≤ 80 mL, maximum flow rate (Qmax) ≤ 15 mL/s, and an International Prostate Symptom Score (IPSS) ≥ 14 were included in the study. A total of 38 patients ranging in age from 52-78 years completed the study. Patients were randomly allocated to receive either TURP or TURPis in a 1:1 ratio. Primary endpoints were: (1) declines in serum sodium (Na+) and hemoglobin (Hb); (2) incidence of TUR syndrome; and (3) changes in IPSS, quality of life (QoL), and maximum flow rate (Qmax). Secondary endpoints included: (1) differences in procedure, irrigation, catheterization, and hospitalization times; (2) variations in blood transfusion, recatheterization, and clot retention rates; (3) changes in prostate specific antigen (PSA), prostate volume (PV), and postvoid residual urine (PVR); and (4) incidences of postoperative complications. Patients were followed for 6 months
RESULTS: The mean PV for the entire study population was 44.1 mL (SD = 2.0; range, 29-78 mL). There were no significant differences between groups on any of the baseline variables. Mean (standard deviation) declines in serum Na+ were 4.8 (1.1) and 0.9 (0.3) mmol/L for the patients receiving TURP and TURPis, respectively (P < .001). Mean declines in Hb were 1.5 (0.6) and 0.7 (0.4) g/dL for the patients receiving TURP and TURPis, respectively (P < .002). The patients receiving TURPis had significantly smaller declines for both of these variables. When compared with the patients receiving TURP, those receiving TURPis had significantly shorter mean times for the procedure (P < .03), irrigation (P < .001), catheterization (P < .02), and hospitalization (P < .02). The patients receiving TURPis had significantly fewer clot retentions (P < .05) than the patients receiving TURP. None of the patients in either group required blood transfusion or demonstrated TUR syndrome. One patient receiving TURP developed a bladder neck contracture; 1 patient receiving TURPis experienced urethral stricture. Efficacy outcomes (IPSS, QoL, Qmax, PSA, PV, and PVR) revealed that all changes from baseline were statistically significant in both groups (P < .05). However, none of the between-group comparisons reached statistical significance.
CONCLUSION: TURPis has the potential to be the new gold standard for BPH treatment. The present study demonstrated that over a 6-month period, TURPis has efficacy similar to TURP. TURPis has additional advantages of smaller declines in serum sodium and hemoglobin, reduced irrigation and catheterization times, shorter hospital stay, and elimination of TUR syndrome.
KEYWORDS: Benign prostatic hyperplasia; Bipolar; Bipolar transurethral resection; Prostate; Transurethral resection syndrome
CORRESPONDENCE: Dr. Taha Abo-Almagd Abdel-Meguid, PO Box 80215, Jeddah 21589, Saudi Arabia (tahaaboalmagd@yahoo.com).
CITATION: UroToday Int J. 2010 Feb;3(1). doi:10.3834/uij.1944-5784.2010.02.05